June 23, 2026
Dr. Francesco Marincola Named Chief Scientific Officer of TAM Global
TAM Global announced the appointment of internationally recognized tumor immunologist Dr. Francesco Marincola as Chief Scientific Officer. The release emphasized his extensive NIH and translational medicine background and described his role overseeing TAM’s scientific strategy across diagnostics, genomics, AI, cellular therapy, and precision medicine initiatives.
Read Release
June 18, 2026
TAM Center Officially Opens its Doors in Mexico: A New Global Hub for Cancer Diagnosis, Regenerative Medicine, and Translational Science
TAM Global is proud to announce the official opening of the TAM Center in Tijuana, Mexico, positioning it as an advanced translational medicine and regenerative healthcare hub. The release highlighted the facility’s genomics capabilities, stem cell manufacturing infrastructure, AI integration, diagnostics partnership with Roche, imaging technologies, and multidisciplinary scientific team focused on cancer, chronic disease, and personalized medicine.
Read Release
June 15, 2026
Breakthrough Immorta Bio Study Collaboration With TAM Global Increases Life Span In Mice over 70% Using Novel Combination Senolytics
Immorta Bio President Thomas Ichim and TAM Global’s Chief Scientific Officer Francesco M. Marincola announced a landmark preclinical breakthrough demonstrating a more than 70% increase in lifespan in mice. The study introduces a first-in-class, dual-modality strategy that combines senolytic immunotherapy with regenerative medicine, pairing SenoVax (an immune-based therapy designed to selectively eliminate senescent cells) with StemCellRevivify, a personalized mesenchymal stem cell platform aimed at restoring tissue function.
Read Release
April 2, 2026
New Paper in Translational Insights Presents a Unifying Theory for How the Immune System Recognizes Cancer
TAM Global announced the publication of a paper proposing a new theory of cancer immunogenicity involving viral mimicry and “cancer dark matter.” The release framed the work as a potential advancement in understanding immune recognition of cancer and future immunotherapy development.
Read Release
March 23, 2026
Translational Insights Launches, Introducing a New Era in Translational Medicine
TAM Global announced the launch of Translational Insights, a new scientific journal led by TAM’s Chief Scientific Officer, Dr. Marincola, focused on rethinking the traditional “bench-to-bedside” model. The journal promotes a human-centered, bidirectional translational medicine framework emphasizing earlier use of human biological data and real-world clinical insights.
Read Release
January 29, 2026
TAM Global Study Challenges Stem Cell Claims for Wharton’s Jelly Commercial Products
TAM Global announced findings from a peer-reviewed study concluding that commercially available Wharton’s jelly products do not contain clinically meaningful quantities of viable stem cells. The release argued for clearer distinctions between structural biologic products and true stem cell therapies and emphasized transparency in regenerative medicine marketing.
Read Release
For TAM media inquiries contact press@thetamcenter.com